CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.7200
-0.0100 (-1.37%)
At close: Apr 1, 2025, 4:00 PM
0.7223
+0.0023 (0.32%)
After-hours: Apr 1, 2025, 4:40 PM EDT

Company Description

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.

Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.

The company was incorporated in 2021 and is based in South San Francisco, California.

CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Christopher Ehrlich

Contact Details

Address:
201 Haskins Way, Suite 230
South San Francisco, California 94080
United States
Phone 215 731 9450
Website cero.bio

Stock Details

Ticker Symbol CERO
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001870404
ISIN Number US71902K1051
Employer ID 87-1088814
SIC Code 2836

Key Executives

Name Position
Christopher B. Ehrlich M.B.A. Chief Executive Officer and Chair
Dr. Lawrence Corey M.D. Co-founder and Head of Scientific Advisory Board
Andrew Albert Kucharchuk M.B.A. Chief Financial Officer
Dr. Kristen Pierce Ph.D. Chief Development Officer

Latest SEC Filings

Date Type Title
Apr 1, 2025 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Feb 13, 2025 424B3 Prospectus
Feb 13, 2025 424B3 Prospectus
Feb 13, 2025 424B3 Prospectus
Feb 13, 2025 424B3 Prospectus
Feb 12, 2025 8-K Current Report
Feb 7, 2025 SCHEDULE 13D/A Filing
Feb 7, 2025 424B3 Prospectus
Feb 6, 2025 8-K Current Report
Feb 5, 2025 EFFECT Notice of Effectiveness